Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network 'Rete Ematologica del Lazio per i Linfomi' (RELLI).
Annibali O, Hohaus S, Marchesi F, Cantonetti M, Di Rocco A, Tomarchio V, Di Napoli A, Pelliccia S, Battistini R, Anticoli Borza P, Abruzzese E, Cenfra N, Andriani A, Tesei C, Alma E, Palombi F, Pupo L, Petrucci L, Becilli M, Maiolo E, Bellesi S, Cuccaro A, D'Alò F, Cox MC. Annibali O, et al. Among authors: andriani a. Leuk Lymphoma. 2019 Dec;60(14):3386-3394. doi: 10.1080/10428194.2019.1633628. Epub 2019 Jul 1. Leuk Lymphoma. 2019. PMID: 31259651
IgM-secreting diffuse large B-cell lymphoma: results of a multicentre clinicopathological and molecular study.
Cox MC, Marcheselli L, Scafetta G, Visco C, Hohaus S, Annibali O, Musuraca G, Fabbri A, Cantonetti M, Pelliccia S, Papotti R, Petrucci L, Tani M, Battistini R, Arcari A, Luminari S, Lopez G, Alma E, Pupo L, Carli G, Marchesi F, Re F, Scarpino S, D'amore ESG, Larocca LM, Bianchi A, Pepe G, Natalino F, Anticoli-Borza P, Cenfra N, Andriani A, Abruzzese E, Tesei C, Leoncini L, Asioli S, Ruco L, Di Napoli A. Cox MC, et al. Among authors: andriani a. Leukemia. 2022 Nov;36(11):2719-2723. doi: 10.1038/s41375-022-01706-x. Epub 2022 Sep 20. Leukemia. 2022. PMID: 36127510 No abstract available.
Preliminary results of a counselling programme for fertility preservation in female cancer patients: The experience of the GEMME DORMIENTI network.
Ciccarone M, Hohaus S, Pulsoni A, Cavaceppi P, Franzò S, Fabbri R, Cudillo L, Battistini R, Di Rocco A, Annibali O, Cox MC, Provenzano I, Abruzzese E, Renzi D, Tesei C, Anticoli Borza P, Cuccaro A, Andriani A, D'Elia GM, Facchiano A, Marchetti P, Cantonetti M. Ciccarone M, et al. Among authors: andriani a. Eur J Cancer Care (Engl). 2020 Jan;29(1):e13174. doi: 10.1111/ecc.13174. Epub 2019 Sep 30. Eur J Cancer Care (Engl). 2020. PMID: 31571303
Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group.
Fazio F, Franceschini L, Tomarchio V, Rago A, Garzia MG, Cupelli L, Bongarzoni V, Andriani A, Gumenyuk S, Tafuri A, Siniscalchi A, Piciocchi A, De Fabritiis P, De Rosa L, Caravita di Toritto T, Annibali O, Cantonetti M, Petrucci MT. Fazio F, et al. Among authors: andriani a. EJHaem. 2022 Jan 15;3(1):121-128. doi: 10.1002/jha2.359. eCollection 2022 Feb. EJHaem. 2022. PMID: 35846211 Free PMC article.
Sequential occurrence of chronic myeloproliferative and lymphoproliferative neoplasms: a collaborative retrospective study by pH-negative MPN latial group.
Breccia M, Petriccione L, Tatarelli C, De Muro M, Trawinska MM, Santopietro M, Spadea A, Di Veroli A, Scalzulli E, Paciaroni K, Tafuri A, Latagliata R, Andriani A, Di Napoli A. Breccia M, et al. Among authors: andriani a. Leuk Lymphoma. 2022 Nov;63(11):2751-2753. doi: 10.1080/10428194.2022.2092859. Epub 2022 Jun 25. Leuk Lymphoma. 2022. PMID: 35758305 No abstract available.
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis.
Bringhen S, Offidani M, Palmieri S, Pisani F, Rizzi R, Spada S, Evangelista A, Di Renzo N, Musto P, Marcatti M, Vallone R, Storti S, Bernardini A, Centurioni R, Aitini E, Palmas A, Annibali O, Angelucci E, Ferrando P, Baraldi A, Rocco S, Andriani A, Siniscalchi A, De Stefano V, Meneghini V, Palumbo A, Grammatico S, Boccadoro M, Larocca A. Bringhen S, et al. Among authors: andriani a. Crit Rev Oncol Hematol. 2018 Oct;130:27-35. doi: 10.1016/j.critrevonc.2018.07.003. Epub 2018 Jul 18. Crit Rev Oncol Hematol. 2018. PMID: 30196909 Free article. Review.
Prognostic factors for thrombosis-free survival and overall survival in polycythemia vera: A retrospective analysis of 623 PTS With long follow-up.
Di Veroli A, Buccisano F, Andriani A, Montanaro M, Latagliata R, Santoro C, Breccia M, Spirito F, Cedrone M, Anaclerico B, Leonetti Crescenzi S, Porrini R, De Muro M, Avvisati G, Tafuri A, Cimino G, Spadea A. Di Veroli A, et al. Among authors: andriani a. Leuk Res. 2018 Jun;69:18-23. doi: 10.1016/j.leukres.2018.03.016. Epub 2018 Mar 31. Leuk Res. 2018. PMID: 29625320 No abstract available.
Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group.
Vozella F, Siniscalchi A, Rizzo M, Za T, Antolino G, Coppetelli U, Piciocchi A, Andriani A, Annibali O, De Rosa L, Cimino G, La Verde G, De Stefano V, Cantonetti M, di Toritto TC, Petrucci MT. Vozella F, et al. Among authors: andriani a. Ann Hematol. 2021 Apr;100(4):1059-1063. doi: 10.1007/s00277-020-04374-y. Epub 2021 Feb 2. Ann Hematol. 2021. PMID: 33528611
Hemoglobin levels and circulating blasts are two easily evaluable diagnostic parameters highly predictive of leukemic transformation in primary myelofibrosis.
Rago A, Latagliata R, Montanaro M, Montefusco E, Andriani A, Crescenzi SL, Mecarocci S, Spirito F, Spadea A, Recine U, Cicconi L, Avvisati G, Cedrone M, Breccia M, Porrini R, Villivà N, De Gregoris C, Alimena G, D'Arcangelo E, Guglielmelli P, Lo-Coco F, Vannucchi A, Cimino G. Rago A, et al. Among authors: andriani a. Leuk Res. 2015 Mar;39(3):314-7. doi: 10.1016/j.leukres.2015.01.001. Epub 2015 Jan 12. Leuk Res. 2015. PMID: 25636356
Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN.
Breccia M, Andriani A, Montanaro M, Abruzzese E, Buccisano F, Cedrone M, Centra A, Villivà N, Celesti F, Trawinska MM, Massaro F, Di Veroli A, Anaclerico B, Colafigli G, Molica M, Spadea A, Petriccione L, Cimino G, Latagliata R. Breccia M, et al. Among authors: andriani a. Ann Hematol. 2017 Mar;96(3):387-391. doi: 10.1007/s00277-016-2884-7. Epub 2016 Nov 26. Ann Hematol. 2017. PMID: 27889820
137 results